Annual report
3034.TEDINET S100YJYW
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥290.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥264.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥180.1bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥170.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥166.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥14.8bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥13.5bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥14.9bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥13.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥9.3bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.1bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.1bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥14.4bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥12.8bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.4bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.2bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.9bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.7bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.5bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥8.5bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥7.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥158.1bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥159.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥117.8bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥101.9bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥96.0bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥98.3bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥97.5bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥59.8bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥62.1bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥52.8bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥43.9bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥21.4bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥26.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥21.0bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥26.9bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.6bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥16.5bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥18.7bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥12.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.5bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.7bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.1bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥9.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥15.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥7.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥8.0bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10.0bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥197.35 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥137.97 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥131.11 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥152.96 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥149.51 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,528.91 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,521.14 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,414.43 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,314.69 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,189.7 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 36.3% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.8% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.9% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.7% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 12.9% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.2% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.9% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 6,247 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 6,254 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 5,856 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 5,746 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 5,620 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥11.2bn | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥9.3bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥8.7bn | 2023-04-01 → 2024-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥8.3bn | 2022-04-01 → 2023-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥7.0bn | 2021-04-01 → 2022-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥9.1bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥7.3bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥8.9bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.3bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥7.0bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥6.6bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.5bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.9bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥6.4bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥8.8bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥6.5bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥6.7bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥6.6bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥5.4bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥123.3bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥123.4bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥93.6bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥77.5bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥67.4bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥57.8bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥65.3bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥65.5bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥58.2bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥52.5bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥46.7bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥40.8bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥11.3bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥13.4bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥235.3 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥174.02 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.61 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥178 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥146.91 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥50 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥34 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥32 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,743.3 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,549.24 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,407.23 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,258.81 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,108.12 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 53.1% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.1% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.1% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.3% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.6% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 14.3% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.8% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.5% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.0% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.0% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 38,902,785 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 38,902,785 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 41 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 48 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 66 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 66 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 56 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 69
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥56m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥75m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥1.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥1.6bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | −¥9.5bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥3.8bn |
| BPOreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥581m |
| BPOreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥85m |
| BPOreportable segment | employees | at 2026-03-31 | 782 pure |
| BPOreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥15.7bn |
| BPOreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥14.3bn |
| BPOreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥1.4bn |
| BPOreportable segment | segment assets | at 2026-03-31 | ¥8.3bn |
| BPOreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.9bn |
| Health Insurance Pharmacyreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥2.2bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥1.6bn |
| Health Insurance Pharmacyreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥177.6bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥177.5bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥124m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2026-03-31 | ¥93.9bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥9.7bn |
| Pharmaceutical Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥6.2bn |
| Pharmaceutical Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥3.6bn |
| Pharmaceutical Businessreportable segment | employees | at 2026-03-31 | 314 pure |
| Pharmaceutical Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥99.0bn |
| Pharmaceutical Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥99.0bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2026-03-31 | ¥65.4bn |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥7.0bn |
| Pharmacyreportable segment | employees | at 2026-03-31 | 5059 pure |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥8.9bn |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥5.3bn |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥292.3bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥290.8bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥1.6bn |
| —segment total | segment assets | at 2026-03-31 | ¥167.6bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥18.6bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥86m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥66m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥9.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥3.5bn |
| BPOreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥108m |
| BPOreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥87m |
| BPOreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥14.9bn |
| BPOreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥13.6bn |
| BPOreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.3bn |
| BPOreportable segment | segment assets | at 2025-03-31 | ¥8.6bn |
| BPOreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Health Insurance Pharmacyreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥6.0bn |
| Health Insurance Pharmacyreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥1.5bn |
| Health Insurance Pharmacyreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥171.7bn |
| Health Insurance Pharmacyreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥171.6bn |
| Health Insurance Pharmacyreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥93m |
| Health Insurance Pharmacyreportable segment | segment assets | at 2025-03-31 | ¥94.8bn |
| Health Insurance Pharmacyreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| Pharmaceutical Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥35.5bn |
| Pharmaceutical Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2.2bn |
| Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥78.7bn |
| Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥78.7bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2025-03-31 | ¥66.2bn |
| Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥5.3bn |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥41.6bn |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥3.8bn |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥265.3bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥264.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.4bn |
| —segment total | segment assets | at 2025-03-31 | ¥169.6bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥17.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,621
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 1 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 6 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 5 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.768 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.785 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.193 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.242 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 1.310 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.020 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.079 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.526 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.502 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.022 | |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 3055000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E03476-000HealthInsurancePharmacyReportableSegmentsMember | 1918000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 38902785 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 38902785 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 38902785 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 38902785 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 12 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 26 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 162 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 101 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 45 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 25941 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 26287 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 28384 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 20453 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 114499 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 107352 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 130 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 117782 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 388600 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 42785 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0730 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0526 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.2947 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.2763 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0003 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.3031 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 7582800 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.2017 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 3782900 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.1006 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 2318800 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0617 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |